Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function (NCT02743468) | Clinical Trial Compass
CompletedNot Applicable
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function
United States20 participantsStarted 2019-01-08
Plain-language summary
Background:
Respiratory diseases affect more than 1 billion people worldwide. They are a growing public health concern. The lungs are constantly exposed to environmental factors such as dust, fumes, microbes, and pollutants. But much is still not known about how these pollutants lead to respiratory illnesses. Researchers want to collect samples from lungs and blood to see how genetics and environmental pollutants affect cellular responses or functioning.
Objectives:
To study how cytochrome P450 epoxygenase pathway enzymes affect macrophage function in the lungs and inflammatory responses.
Eligibility:
Adults ages 18 65 who can have a bronchoscopy.
Design:
All study visits will take place at the NIEHS Clinical Research Unit in Research Triangle Park, NC.
At study visit 1, participants will be screened with medical history and physical exam. They will have blood and urine tests. They will take tests that measure their lung function. They will answer questionnaires. Before the visit, they will be given a list of medicines they cannot take. They also must not have caffeine on the day of their visit. The visit will last about 3 hours.
At study visit 2, participants will give blood samples. They will undergo bronchoscopy. For this, they will get an intravenous line in a vein to get sedatives. Their airways will be numbed. Cells will be collected from their lungs. They will fast for 8 hours before the visit. They must have someone else drive them home from the visit. The visit will last about 3-4 hours.
Participants will get a follow-up phone call about 1 day after study visit 2.
...
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18 to 65 years, inclusive (males and females)
✓. Able to travel to the NIEHS CRU for required study visits
✓. Able to present a valid government-issued form of identification for entry to the NIEHS campus
✓. Able to fast for 8 hours prior to the visit where bronchoscopy occurs
✓. Has a responsible party who is willing and able to attend Visit 2 and drive the participant away from the CRU after completion of Visit 2, if the participant elects to undergo conscious sedation
✓. Genotype information available for relevant CYP2J2 and EPHX2 polymorphisms, which indicates:
Exclusion criteria
✕. Current pregnancy or lactation, as medications used during the bronchoscopy can be excreted in the breast milk of lactating mothers
✕. Current smoker or significant second-hand smoke exposure (defined by urine cotinine \>200 ng/mL at screening)
✕
What they're measuring
1
The primary outcome measure will evaluate macrophage phagocytosis of fluorescein isothiocyanate (FITC)-labeled beads and bacteria (Streptococcus pneumoniae) in an ex vivo assay, comparing alveolar macrophages from groups of individuals with and ...
Timeframe: Cross-sectional
Trial details
NCT IDNCT02743468
SponsorNational Institute of Environmental Health Sciences (NIEHS)
✕. For asthmatics, any indication of moderate or severe asthma such as:
✕. Bleeding disorders or regular use of aspirin or other non-steroidal anti-inflammatory drugs (which inhibit platelet function) or other drugs that prolong bleeding time such as warfarin, heparin or derivatives, or clopidogrel and related ADP inhibitors
✕. Sickle cell disease or GP6 deficiency
✕. Facial deformity or major facial surgery
✕. Asthma exacerbation or respiratory infection 4 weeks prior to study visit